Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30441
Title: Prevalence, risk factors, and prognosis of drug-resistant epilepsy in autoimmune encephalitis.
Austin Authors: Wesselingh, Robb;Broadley, James;Buzzard, Katherine;Tarlinton, David;Seneviratne, Udaya;Kyndt, Chris;Stankovich, Jim;Sanfilippo, Paul;Nesbitt, Cassie;D'Souza, Wendyl;Macdonell, Richard A L ;Butzkueven, Helmut;O'Brien, Terence J;Monif, Mastura
Affiliation: Department of Neurosciences, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Level 6, Alfred Centre, 99 Commercial Road, Melbourne, Victoria 3004, Australia..
Department of Neuroscience, Eastern Health, Level 2, 5 Arnold Street, Box Hill, Victoria 3128, Australia..
Department of Neurology, Melbourne Health, 300 Grattan Street, Parkville, Victoria 3050, Australia..
Department of Immunology and Pathology, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Level 6, Burnett Building, 89 Commercial Road, Melbourne, Victoria 3004, Australia..
Department of Neurosciences, Monash Health, Clayton Road, Clayton, Victoria 3168, Australia..
Department of Neurology, University Hospital of Geelong, Level 2, Kardinia House, Bellerine Street, Geelong, Victoria 3220, Australia..
Department of Neurosciences, Building D - Daly Wing, Level 5, St Vincent's Hospital, Fitzroy, Victoria 3065, Australia..
Neurology
Department of Neurology, Alfred Health, Level 6, Alfred Centre, 99 Commercial Road, Melbourne, Victoria 3004, Australia..
Issue Date: Jul-2022
Date: 2022
Publication information: Epilepsy & behavior : E&B 2022; 132: 108729
Abstract: To evaluate the prevalence and biomarkers of drug-resistant epilepsy (DRE) in patients with autoimmune encephalitis (AIE). Sixty-nine patients with AIE were recruited retrospectively and electroencephalographies (EEGs) were reviewed using a standard reporting proforma. Associations between EEG biomarkers and DRE development at 12 months were examined using logistic regression modeling and were utilized to create a DRE risk score. Sixteen percent of patients with AIE developed DRE at 12-month follow-up. The presence of status epilepticus (SE) (OR 11.50, 95% CI [2.81, 51.86], p-value <0.001), temporal lobe focality (OR 9.90, 95% CI [2.60, 50.71], p-value 0.001) and periodic discharges (OR 19.12, 95% CI [3.79, 191.10], p-value 0.001) on the admission EEG were associated with the development of DRE at 12 months. These variables were utilized to create a clinically applicable risk score for the prediction of DRE development. Drug-resistant epilepsy is an infrequent complication of AIE. Electroencephalography changes during the acute illness can predict the risk of DRE at 12 months post-acute AIE. The identified EEG biomarkers provide the basis to generate a clinically applicable prediction tool which could be used to inform treatment, prognosis, and select patients for acute treatment trials.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30441
DOI: 10.1016/j.yebeh.2022.108729
ORCID: 0000-0001-6604-3968
Journal: Epilepsy & behavior : E&B
PubMed URL: 35623203
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35623203/
Type: Journal Article
Subjects: Autoimmune encephalitis
Drug-resistant epilepsy
Electroencephalogram
Prognosis
Status epilepticus
Appears in Collections:Journal articles

Show full item record

Page view(s)

32
checked on Jun 16, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.